Payment overview · 2025
General Payments
$2,342.59
114 reported records · 24 companies
Healthcare provider profile · identity verified
Mohammad A Alsoub, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine · DICKSON, TN · NPI 1063407534
Verified facts
What the public records show
CMS Open Payments records show Mohammad A Alsoub, MD received $2,342.59 in general payments during 2025 across 114 reported records.
Ethicon Inc. accounted for 13.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Wakix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Trelegy Ellipta by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wakix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 370 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ethicon Inc. | Unresolved — no canonical attribution shown | $309.70 | 13.2% | 5 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $264.93 | 11.3% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $249.17 | 10.6% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $205.09 | 8.8% | 9 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $186.56 | 8.0% | 13 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $172.41 | 7.4% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $172.36 | 7.4% | 11 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $162.47 | 6.9% | 5 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $139.17 | 5.9% | 12 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $57.55 | 2.5% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $57.48 | 2.5% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $38.84 | 1.7% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $37.42 | 1.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.04 | 1.6% | 2 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $37.03 | 1.6% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.59 | 1.6% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $30.92 | 1.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $26.19 | 1.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.44 | 1.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $24.25 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.99 | 0.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.96 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.35 | 0.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $13.68 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,177.74 | 111 |
| Education | $164.85 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., SANOFI-AVENTIS U.S. LLC | $402.25 | 23 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $309.70 | 5 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $264.93 | 5 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $214.33 | 16 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $186.56 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $153.05 | 6 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $147.29 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $144.90 | 4 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $121.79 | 11 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $112.67 | 3 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $84.54 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $69.31 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $38.84 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $37.42 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $37.04 | 2 | 2025 |
Source payment records
|
|||||
| Monarch Normalized: monarch |
Device | Medical Device Business Services, Inc. | $37.03 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $35.09 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.84 | 4 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $30.92 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $26.19 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $25.44 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| XOLAIR Normalized: xolair |
Drug | Novartis Pharmaceuticals Corporation | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 410 | exact normalized | Medicare Part D |
| WAKIX wakix |
2025 | Wakix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
410 | 105 |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
370 | 23 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 475 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 419 | 110 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 410 | 105 |
| Furosemide | Furosemide | 375 | 17 |
| Divalproex Sodium | Divalproex Sodium | 372 | 18 |
| Eliquis | Apixaban | 370 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 18 |
| Sertraline Hcl | Sertraline Hcl | 356 | 12 |
| Trazodone Hcl | Trazodone Hcl | 295 | 26 |
| Prednisone | Prednisone | 287 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 276 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 17 |
| Losartan Potassium | Losartan Potassium | 252 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 240 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 226 | suppressed |
| Olanzapine | Olanzapine | 221 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 215 | suppressed |
| Famotidine | Famotidine | 213 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 207 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 206 | suppressed |
| Lisinopril | Lisinopril | 190 | suppressed |
| Simvastatin | Simvastatin | 188 | suppressed |
| Risperidone | Risperidone | 174 | suppressed |
| Mirtazapine | Mirtazapine | 171 | 12 |
| Gabapentin | Gabapentin | 169 | suppressed |
| Omeprazole | Omeprazole | 164 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 160 | 38 |
| Memantine Hcl | Memantine Hcl | 146 | suppressed |
| Levetiracetam | Levetiracetam | 144 | suppressed |
| Carvedilol | Carvedilol | 135 | suppressed |
| Baclofen | Baclofen | 129 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 121 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 103 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 102 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 99 | suppressed |
| Lamotrigine | Lamotrigine | 97 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 95 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 91 | suppressed |
| Metformin Hcl | Metformin Hcl | 88 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 87 | suppressed |
| Lorazepam | Lorazepam | 78 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 71 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 71 | suppressed |
| Finasteride | Finasteride | 65 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 63 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | suppressed |
| Meloxicam | Meloxicam | 59 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 57 | suppressed |
| Olanzapine Odt | Olanzapine | 56 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 55 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 54 | 14 |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 50 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | suppressed |
| Cholestyramine Light | Cholestyramine | 47 | suppressed |
| Glipizide | Glipizide | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 44 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 43 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 42 | suppressed |
| Carbamazepine Er | Carbamazepine | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 12 |
| Primidone | Primidone | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Xifaxan | Rifaximin | 37 | suppressed |
| Lactulose | Lactulose | 36 | 21 |
| Budesonide | Budesonide | 35 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Fycompa | Perampanel | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 30 | suppressed |
| Metolazone | Metolazone | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Novolog | Insulin Aspart | 23 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Insulin Aspart | Insulin Aspart | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Insulin Lispro | Insulin Lispro | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Ziprasidone Mesylate | Ziprasidone Mesylate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Phenazopyridine Hcl | Phenazopyridine Hcl | 13 | suppressed |
| Wakix | Pitolisant Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,342.59 · 114 records | Ethicon Inc. | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, COMIRNATY, DUPIXENT, FASENRA, Hillrom - Vest System Model 105 Home Care, INSPIRE, Monarch, Monarch Platform, NUCALA, OPSUMIT, Ohtuvayre, PREVNAR 20, PURIFIED CORTROPHIN GEL, SMARTVEST, Sunosi, TEZSPIRE, TRELEGY ELLIPTA, UPTRAVI, Vest Therapy Und, WAKIX, XOLAIR, YUPELRI, ZEPBOUND, ZERBAXA | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error